IDEXX Laboratories, Inc. vs Invesco NASDAQ 100 ETF — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Invesco NASDAQ 100 ETF trades at $290.53. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | QQQM | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $307.23 |
52-Week Low | $520.87 | $228.02 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
QQQM trades at $286.58 with minimal daily movement (+0.09%), reflecting a bearish technical signal amid neutral oscillators. The ETF's lower 0.15% expense ratio compared to QQQ attracts long-term growth investors, while recent Nasdaq-100 inclusion of SpaceX (1% weighting) adds diversification. Support levels cluster near $285-$283, with resistance at $288-$292.
Outlook remains tied to tech sector performance, with AI infrastructure spending by holdings like Amazon ($200B annual CapEx guidance) as a key catalyst. Risks include stretched valuations and rising AI competition. The bearish technical bias suggests near-term consolidation, but the fund's cost efficiency supports long-term growth exposure.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →